PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of Fibrosis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Transforming growth factor beta (TGFβ) induced differentiation of human lung fibroblasts to myofibroblasts is a key event in the pathogenesis of pulmonary fibrosis. Although the typical TGFβ signaling pathway involves the Smad family of transcription factors, we have previously reported that peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands inhibit TGFβ-mediated differentiation of human lung fibroblasts to myofibroblasts via a Smad-independent pathway. TGFβ also activates the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) pathway leading to phosphorylation of Akt(S473). Here, we report that PPAR-γ ligands, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and 15-deoxy-(12,14)-15d-prostaglandin J(2) (15d-PGJ(2)), inhibit human myofibroblast differentiation of normal and idiopathic pulmonary fibrotic (IPF) fibroblasts, by blocking Akt phosphorylation at Ser473 by a PPAR-γ-independent mechanism. The PI3K inhibitor LY294002 and a dominant-negative inactive kinase-domain mutant of Akt both inhibited TGFβ-stimulated myofibroblast differentiation, as determined by Western blotting for α-smooth muscle actin and calponin. Prostaglandin A(1) (PGA(1)), a structural analogue of 15d-PGJ(2) with an electrophilic center, also reduced TGFβ-driven phosphorylation of Akt, while CAY10410, another analogue that lacks an electrophilic center, did not; implying that the activity of 15d-PGJ(2) and CDDO is dependent on their electrophilic properties. PPAR-γ ligands inhibited TGFβ-induced Akt phosphorylation via both post-translational and post-transcriptional mechanisms. This inhibition is independent of MAPK-p38 and PTEN but is dependent on TGFβ-induced phosphorylation of FAK, a kinase that acts upstream of Akt. Thus, PPAR-γ ligands inhibit TGFβ signaling by affecting two pro-survival pathways that culminate in myofibroblast differentiation. Further studies of PPAR-γ ligands and small electrophilic molecules may lead to a new generation of anti-fibrotic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 PPAR-γ ligands inhibit TGFβ-induced Akt phosphorylation and myofibroblast differentiation in a PPAR-γ-independent but electrophilic carbon-dependent manner. HLF cells were treated with indicated compounds and/or TGFβ (5ng/ml) for 48 hours. Immunoblots were performed to assess the expression of indicated proteins. Protein lysates from all the indicated samples were electrophoretically separated on the same gel, and representative lanes from a single experiment are shown here. A, the ability of PPAR-γ ligands (CDDO (1µM) and 15d-PGJ2 (5µM)) to reduce p-Akt was not altered upon GW9662-mediated inhibition of PPAR-γ. GW9662 (5µM) inhibits PPAR-γ activity by a covalent bond formation with PPAR-γ protein [36]. R.P. indicates relative changes in Akt phosphorylation compared to control sample, and R.E., relative changes in expression compared to control sample. B, PPAR-γ ligands contain electrophilic carbons. Here, positions of the electrophilic carbons in the structures of the compounds are marked. CAY10410 and PGA1 are structural analogues of 15-d-PGJ2. PGA1 has an electrophilic center but CAY10410 does not. DSPS, like CDDO, has two electrophilic centers. Cells were pre-treated with CAY10410 (5µM), PGA1 (10µM) and DSPS (10µM) for 30 minutes C, only compounds with an electrophilic carbon are able to reduce Akt phosphorylation, indicating that presence of an electrophilic carbon is essential for the observed reduction in the phosphorylation of Akt. All the experiments were performed in triplicate and representative images are shown here.](https://figures.cochat.ai/paper-figures/42fe33a117e847be83731e464fb63bd7/ppar-ligands-repress-tgf-induced-myofibroblast-differentiation-by-targeting-the-figure-3.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Integrin-regulated FAK–Src signaling in normal and cancer cells
Mitra, S. K., & Schlaepfer, D. D. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.011 · Cited by 1,590 · cited 1×
“However, it is widely accepted that integrins are able to activate TGFb [56] and FAK [57,58],”
BackgroundSime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Self-citationSignaling cross-talk between TGF-β/BMP and other pathways
Guo, X., & Wang, X.-F. (2009) · Cell Research · doi:10.1038/cr.2008.302 · Cited by 1,015 · cited 3×
“Binding of active TGFb to its receptor triggers several signaling pathways [8,9], including the well-characterized Smad pathway and the PI3K/Akt (phosphotidylinositol-3-kinase/Protein Kinase B/PKB) pathway [7,10,11].”
Background15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Calalb, M. B., Polte, T. R., & Hanks, S. K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.954 · Cited by 985 · cited 1×
“Increase in phosphorylation of FAK correlates with its increased catalytic activity [20,21] and is required for the recruitment of p85, a regulatory subunit of PI3K [22].”
BackgroundInterleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., & Glass, C. K. (1999) · Nature · doi:10.1038/22572 · Cited by 855 · cited 1×
“, have shown that PPAR-γ ligands also have effects that are independent of PPAR-γ activity. To examine if inhibition of Akt phosphorylation by PPAR-γ ligands was dependent on the functional activity of PPAR-γ, we used a pharmacological approach involving a PPAR-γ antagonist GW9662, an irreversible PPAR-γ antagonist th…”
Method
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 587
“Although PPARα-regulated lipid metabolism has not previously been shown to be protective against fibrosis in direct studies, the transcription factor PPARγ has been shown in several organs to protect against fibrosis(38), implying that regulation of lipid and fatty acid oxidation is critical in fibrotic responses to c…”
BackgroundTargeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Kottmann, R. M., Kulkarni, A. A., Smolnycki, K. A., Lyda, E., Dahanayake, T., Salibi, R., Honnons, S., Jones, C., Isern, N. G., Hu, J. Z., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0084oc · Cited by 415
“Primary human lung fibroblasts were cultured to subconfluence on glass chamber slides under standard conditions described above, and slides were prepared using aSMA (Sigma Aldrich) and Alexa Fluor 488 (Invitrogen, Carlsbad, CA) as previously described (33).”
MethodSelf-citationLiby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
“In addition to the studies described above on the PI3K/Akt pathway, a proteomics analysis of potential SO binding partners found that several components of the PI3K/AKT/mTOR pathway are highly enriched, suggesting that mTOR may be a triterpenoid target (Yore et al., 2011).”
BackgroundInfluentialMeiners, S., Eickelberg, O., & Königshoff, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186914 · Cited by 340
Cellular and molecular mechanisms of intestinal fibrosis
Speca, S. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i28.3635 · Cited by 272
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Myofibroblast differentiation and survival in fibrotic disease
Kis, K., Liu, X., & Hagood, J. S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001967 · Cited by 224
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Oncotarget · doi:10.18632/oncotarget.21234 · Cited by 204
“PPAR γ targets PI3K/Akt for repress TGF-β1-induced myofibroblast differentiation [330].”
BackgroundTGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts
Vallée, A., & Lecarpentier, Y. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0362-3 · Cited by 194
Different Gene Expression Patterns in Human Papillary and Reticular Fibroblasts
Janson, D. G., Saintigny, G., van Adrichem, A., Mahé, C., & El Ghalbzouri, A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.192 · Cited by 183
“Several validated, reticular markers are associated with myofibroblasts: calponin 1, PPP1R14A, and transglutaminase 2 (Tomasek et al., 2006; Huang et al., 2009; Kulkarni et al., 2011).”
BackgroundLatella, G., Rogler, G., Bamias, G., Breynaert, C., Florholmen, J., Pellino, G., Reif, S., Speca, S., & Lawrance, I. C. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.03.008 · Cited by 164
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Epithelial-mesenchymal transition: An emerging target in tissue fibrosis
Li, M., Luan, F., Zhao, Y., Hao, H., Zhou, Y., Han, W., & Fu, X. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215597194 · Cited by 151
“A focal adhesion kinase inhibitor was also capable of reversing the myofibroblast phenotype.140 In addition, two previous studies have reported that capsaicin, the pungentphenolic constituent of various peppers, can induce the dedifferentiation of myofibroblasts to hepatic stellate cells by anti-fibrotic and anti-infl…”
BackgroundThe Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders
Di Gregorio, J., Robuffo, I., Spalletta, S., Giambuzzi, G., De Iuliis, V., Toniato, E., Martinotti, S., Conti, P., & Flati, V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607483 · Cited by 145
“PPAR-γ activators may reverse the fibrotic state and some of these activators are giving good results, at least in experimental setups (Kulkarni et al., 2011; Xu et al., 2017; Di Gregorio et al., 2017).”
BackgroundMolecular networks underlying myofibroblast fate and fibrosis
Stempien-Otero, A., Kim, D.-H., & Davis, J. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.05.002 · Cited by 143
“In lung tissue, focal-adhesion mediated myofibroblast differentiation also depends on AKT signaling, supporting the role of PI3K/AKT in fibroblast mechanotransduction [115].”
BackgroundPiperine Attenuates Pathological Cardiac Fibrosis Via PPAR-γ/AKT Pathways
Ma, Z., Yuan, Y., Zhang, X., Xu, S., Wang, S., & Tang, Q. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.021 · Cited by 142
“found that the electrophilic center present in PPAR-γ ligands is of great importance to their ability to suppress phosphorylation of AKT (Kulkarni et al., 2011).”
BackgroundChen, T., Zhang, Y., Liu, Y., Zhu, D., Yu, J., Li, G., Sun, Z., Wang, W., Jiang, H., & Hong, Z. (2019) · Aging · doi:10.18632/aging.102263 · Cited by 134
“PPAR-γ is reported to suppress transforming growth factor (TGF)β signaling, which affects two pro-survival pathways [27].”
BackgroundArtemisinin and artemisinin derivatives as anti-fibrotic therapeutics
Dolivo, D., Weathers, P., & Dominko, T. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.001 · Cited by 132
Yun, S., Kim, S., & Kim, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00162 · Cited by 130
“PPAR-γ agonists attached to these receptors can prevent fibrosis induced by activated macrophages or by TGF-β1 through inhibiting fibroblast migration and proliferation (Ricote et al., 1998; Odegaard et al., 2007; Kulkarni et al., 2011).”
BackgroundThe role of natural products in revealing NRF2 function
Zhang, D. D., & Chapman, E. (2020) · Natural Product Reports · doi:10.1039/c9np00061e · Cited by 124
Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway
Saito, S., Zhuang, Y., Shan, B., Danchuk, S. D., Luo, F., Korfei, M., Günther, A., & Lasky, J. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186615 · Cited by 127
FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis
Al-tamari, H. M., Dabral, S., Schmall, A., Sarvari, P., Ruppert, C., Paik, J., DePinho, R. A., Grimminger, F., Eickelberg, O., Günther, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606261 · Cited by 130
“Next to the classical TGF-b1 signaling engaging SMAD2/3, SMAD-independent pathways including PI3K/AKT have been shown to take a part in TGF-b1-induced mesenchymal transition (Wang et al, 2006; Kolosionek et al, 2009; Conte et al, 2011, 2013; Kulkarni et al, 2011).”
BackgroundNrf2 acts cell-autonomously in endothelium to regulate tip cell formation and vascular branching
Wei, Y., Gong, J., Thimmulappa, R. K., Kosmider, B., Biswal, S., & Duh, E. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309276110 · Cited by 113
“Nrf2 has been shown to be activated via phosphorylation by PI3K/Akt (29), and pharmacological activation of Nrf2 leads to inhibition of Akt phosphorylation in cancer cells (30–32) and myofibroblasts (33).”
BackgroundOh, S., Lee, J. H., Kim, H. M., Batsukh, S., Sung, M. J., Lim, T. H., Lee, M. H., Son, K. H., & Byun, K. (2023) · Cells · doi:10.3390/cells12091320 · Cited by 128
“Moreover, TGF-β1 promotes the proliferation of fibroblasts and differentiation into myofibroblasts via the PI3-kinase p85α/AKT pathway [58,59].”
BackgroundLakota, K., Wei, J., Carns, M., Hinchcliff, M., Lee, J., Whitfield, M. L., Sodin-Semrl, S., & Varga, J. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3827 · Cited by 100
“Exposure of fibroblasts to pharmacological PPAR-g ligands resulted in suppression of collagen synthesis, myofibroblast differentiation, and other TGF-b-induced fibrotic responses in vitro [4,9,10].”
BackgroundTsurutani, Y., Fujimoto, M., Takemoto, M., Irisuna, H., Koshizaka, M., Onishi, S., Ishikawa, T., Mezawa, M., He, P., Honjo, S., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.106 · Cited by 102
González, E. G., Selvi, E., Balistreri, E., Akhmetshina, A., Palumbo, K., Lorenzini, S., Lazzerini, P. E., Montilli, C., Capecchi, P. L., Lucattelli, M., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200314 · Cited by 106
Hanging in the balance: endogenous anti‐inflammatory mechanisms in tissue repair and fibrosis
Ariel, A., & Zeituni-Timor, O. (2012) · The Journal of Pathology · doi:10.1002/path.4108 · Cited by 104
Selenium and Selenoproteins in Gut Inflammation—A Review
Nettleford, S. K., & Prabhu, K. S. (2018) · Antioxidants · doi:10.3390/antiox7030036 · Cited by 96
“For instance, PPARγ disrupts the transforming growth factor beta/mothers against decapentaplegic homolog 3 (TGF-β/SMAD3) pathway, which is involved in the formation of fibrotic tissues in a number of organs including the intestine, thus preventing the differentiation and activation of myofibroblasts [73,74].”
BackgroundLang, N. J., Gote-Schniering, J., Porras-Gonzalez, D., Yang, L., Sadeleer, L. D., Jentzsch, R. C., Shitov, V. A., Zhou, S., Ansari, M., Agami, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0908 · Cited by 104
“4H), all previously implicated in the pathogenesis of PF ( 42 – 46 ).”
BackgroundAKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation
Nie, Y., Sun, L., Wu, Y., Yang, Y., Wang, J., He, H., Hu, Y., Chang, Y., Liang, Q., Zhu, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601503 · Cited by 93
“well established that the PI3K/AKT signaling pathway has a critical function in pulmonary fibrosis (34, 35), but the role of the three isoforms of AKT in IPF has not been defined.”
Reversal of myofibroblast differentiation: A review
Yang, X., Chen, B., Liu, T., & Chen, X. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.04.007 · Cited by 90
Gene therapy in the Cornea: 2005–present
Mohan, R. R., Tovey, J. C. K., Sharma, A., & Tandon, A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.09.001 · Cited by 85
“Gene therapy employing PPAR γ , a nuclear hormone receptor with immunomodulatory functions, has been evaluated extensively for non-ocular tissues (Lewis et al., 2008; Klotz et al. 2009; Kulkarni et al., 2011).”
BackgroundRegulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 88
The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches
Wang, Y., Wei, J., Deng, H., Zheng, L., Yang, H. Y., & Lv, X. (2022) · Antioxidants · doi:10.3390/antiox11091685 · Cited by 95
Papillary fibroblasts differentiate into reticular fibroblasts after prolonged in vitro culture
Janson, D., Saintigny, G., Mahé, C., & Ghalbzouri, A. E. (2012) · Experimental Dermatology · doi:10.1111/exd.12069 · Cited by 91
“In addition, the markers used for reticular fibroblasts (CNN1 and TGM2) both have been implicated in myofibroblast function and the contractile apparatus of cells and CNN1 is often used as a marker of smooth muscle tissue (26, 27).”
BackgroundDuke, K. S., & Bonner, J. C. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1498 · Cited by 88
Wei, J., Zhu, H., Komura, K., Lord, G., Tomčík, M., Wang, W., Doniparthi, S., Tamaki, Z., Hinchcliff, M., Distler, J. H. W., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202716 · Cited by 84
Bozaykut, P., Karademir-Yilmaz, B., Yazgan, B., Sözen, E., Siow, R. C. M., Mann, G. E., & Özer, N. K. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.02.017 · Cited by 84
Differential expression of long non-coding RNAs in bleomycin-induced lung fibrosis
Cao, G., Zhang, J., Wang, M., Song, X., Liu, W., MAO, C., & Lv, C. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1404 · Cited by 75
“Further investigation of PPAR-γ ligands and small electrophilic molecules may lead to a new generation of anti-fibrotic therapeutics (42,43).”
Bossini‐Castillo, L., López‐Isac, E., & Martin, J. J. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.005 · Cited by 85
The Role of PPAR Gamma in Systemic Sclerosis
Dantas, A. T., Pereira, M. C., Rêgo, M. J. B. D. M., da Rocha, L. F., Pitta, I. D. R., Marques, C. D. L., Duarte, Â. L. B. P., & Pitta, M. G. D. R. (2015) · PPAR Research · doi:10.1155/2015/124624 · Cited by 73
“This review focused on recent studies that identified PPAR𝛾 as an important novel pathway with critical roles in regulating connective tissue homeostasis, with emphasis on skin and lung fibrosis and its role in systemic sclerosis.”
BackgroundLandi, C., Bargagli, E., Carleo, A., Bianchi, L., Gagliardi, A., Prasse, A., Perari, M. G., Refini, R. M., Bini, L., & Rottoli, P. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400001 · Cited by 67
“This ligand-activated nuclear receptor is also extensively studied for its anti-inflammatory and antifibrotic activity [56].”
BackgroundFibroblasts: Heterogeneous Cells With Potential in Regenerative Therapy for Scarless Wound Healing
Zou, M., Teng, Y., Wu, J., Liu, S., Tang, X., Jia, Y., Chen, Z.-H., Zhang, K., Sun, Z., Li, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.713605 · Cited by 72
“…markers that are associated with myofibroblasts, such as calponin 1, peroxisome proliferator-activated receptor gamma and transglutaminase 2, which directly corresponds to Frs and F-DHJs from the deep dermis and the junction (Ali-Bahar et al., 2004; Wang et al., 2008; Kulkarni et al., 2011).”
BackgroundPotent natural products and herbal medicines for treating liver fibrosis
Chen, S.-R., Chen, X.-P., Lu, J.-J., Wang, Y., & Wang, Y.-T. (2015) · Chinese Medicine · doi:10.1186/s13020-015-0036-y · Cited by 64
Hou, X., Tian, J., Geng, J., Xiao, L., Tang, X., Zhang, J., & Bai, X. (2016) · Oncotarget · doi:10.18632/oncotarget.10283 · Cited by 67
“Others have demonstrated protection against TGF-β1-induced myofibroblast transdifferentiation in cells treated with PPARγ activators [42].”
Backgroundda Silva, B. D. O., Ramos, L. F., & Moraes, K. C. M. (2017) · Cell Biology International · doi:10.1002/cbin.10790 · Cited by 64
“…in vivo and in vitro assays that the overexpression of PPAR-y ameliorates established steatohepatitis and fibrosis, reinforcing the positive effect of this transcriptional factor in the controlling of hepatic fibrosis (Kulkarni et al., 2011; Zhang et al., 2012, 2013; Sharvit et al., 2013).”
BackgroundThermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122537 · Cited by 63
“Inhibition of the PI3K/Akt pathway suppresses collagen synthesis in human and rat hepatic stellate cells [141,142] and protects against pulmonary and kidney fibrosis [143,144].”
BackgroundInhibitory Effects of PPARγ Ligands on TGF-β1–Induced Corneal Myofibroblast Transformation
Jeon, K., Kulkarni, A. A., Woeller, C. F., Phipps, R. P., Sime, P. J., Hindman, H. B., & Huxlin, K. R. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.026 · Cited by 61
Self-citationOlsen, K. C., Epa, A. P., Kulkarni, A. A., Kottmann, R. M., McCarthy, C. E., Johnson, G. V. W., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0092oc · Cited by 67
Self-citationLucarini, L., Durante, M., Lanzi, C., Pini, A., Boccalini, G., Calosi, L., Moroni, F., Masini, E., & Mannaioni, G. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12967 · Cited by 57
“Fibroblasts contribute to the onset of the disease by directly secreting TGF-b, thus inducing differentiation of myofibroblasts [58], profoundly affecting epithelial and airway smooth muscle cells [59] and increasing extracellular matrix secretion.”
BackgroundWang, R., Xu, B., & Xu, H. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000456046 · Cited by 63
Wei, J., Bhattacharyya, S., Jain, M., & Varga, J. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010103 · Cited by 67
Li, J., Li, P., Zhang, G., Qin, P., Zhang, D., & Zhao, W. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02747-9 · Cited by 60
Epa, A. P., Thatcher, T. H., Pollock, S. J., Wahl, L. A., Lyda, E., Kottmann, R. M., Phipps, R. P., & Sime, P. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135266 · Cited by 61
“Whole cell lysates were prepared using NP-40 lysis buffer with protease inhibitors (SigmaAldrich) and analyzed as previously described [26].”
MethodResultSelf-citationThe Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
Kulkarni, A. A., Thatcher, T. H., Hsiao, H.-M., Olsen, K. C., Kottmann, R. M., Morrissette, J., Wright, T. W., Phipps, R. P., & Sime, P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063798 · Cited by 59
“PI3K-Akt is a pro-survival and anti-apoptosis factor that is activated in fibrosis and inhibited by CDDO [10].”
BackgroundSelf-citationWygrecka, M., Zakrzewicz, D., Taborski, B., Didiášová, M., Kwapiszewska, G., Preissner, K. T., & Markart, P. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0097oc · Cited by 57
Li, X., Li, L., Lei, W., Chua, H. Z., Li, Z., Huang, X., Wang, Q., Li, N., & Zhang, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111979 · Cited by 59
Merkt, W., Zhou, Y., Han, H., & Lagares, D. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12952 · Cited by 71
Liu, H., Wang, X., Liu, S., Li, H., Yuan, X., Feng, B., Bai, H., Zhao, B., Chu, Y., & Li, H. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.11.016 · Cited by 52
“To elucidate the underlying molecular mechanism of action of iR-23b, we determined the expression of signalling molecules nvolved in PI3K-AKT signal transduction, which promotes fibrois and diabetic nephropathy (Kulkarni et al., 2011; Miyoshi et al., 013).”
BackgroundThe emerging roles of β-arrestins in fibrotic diseases
Gu, Y.-J., Sun, W., Zhang, S., Wu, J., & Wei, W. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.74 · Cited by 57
Targeting Focal Adhesion Kinase in Fibrotic Diseases
Lagares, D., & Kapoor, M. (2012) · BioDrugs · doi:10.1007/s40259-012-0003-4 · Cited by 58
Cui, Y., Xin, H., Tao, Y., Mei, L., & Wang, Z. (2020) · Phytotherapy Research · doi:10.1002/ptr.6857 · Cited by 52
Mukherjee, S., Sheng, W., Michkov, A. V., Sriarm, K., Sun, R., Dvorkin‐Gheva, A., Insel, P. A., & Janssen, L. J. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00403.2018 · Cited by 54
“Stimulation of PPAR- also exerts antifibrotic actions in HPFs by suppressing PI3K-Akt signaling (11).”
BackgroundIsolation of human nasoseptal chondrogenic cells: A promise for cartilage engineering
do Amaral, R. J. F. C., Pedrosa, C. D. S. G., Kochem, M. C. L., Silva, K. R., Aniceto, M., Cláudio-da-Silva, C. S., Borojević, R., & Baptista, L. S. (2011) · Stem Cell Research · doi:10.1016/j.scr.2011.09.006 · Cited by 52
Samah, M., El-Aidy, A. E.-R., Tawfik, M. K., & Ewais, M. M. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.05.026 · Cited by 50
López‐Isac, E., Bossini‐Castillo, L., Simeón‐Aznar, C. P., Egurbide, M. V., Sancho, J. J. A., Callejas-Rubio, J. L., Román‐Ivorra, J. A., Freire, M., Beretta, L., Santaniello, A., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4432 · Cited by 53
“Thus, it has been reported that fibroblasts exposure to pharmacologic PPARG ligands give rise to suppression of collagen synthesis, myofibroblast differentiation, and other TGF-β-induced fibrotic responses in vitro [19-21].”
BackgroundLoss of PPARγ expression by fibroblasts enhances dermal wound closure
Sha, W., Thompson, K., South, J., Baron, M., & Leask, A. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-5 · Cited by 45
“enhanced phosphorylation of Akt, a protein that is phosphorylated downstream of TGFb and has previously been shown to be activated in fibrosis and to be modified by PPARg [10-14], was also observed in the skin of day 7 and day 10 wounds of PPARg-deficient animals (Figure 6, p-Akt).”
BackgroundBhargava, P., Verma, V. K., Malik, S., Khan, S. I., Bhatia, J., & Arya, D. S. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22283 · Cited by 45
Younis, N. S., Ghanim, A. M. H., Elmorsy, M. A., & Metwaly, H. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-91666-6 · Cited by 47
RetractedGene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis
Ippolito, D. L., AbdulHameed, M. D. M., Tawa, G. J., Baer, C. E., Permenter, M. G., McDyre, B. C., Dennis, W. E., Boyle, M. H., Hobbs, C. A., Streicker, M. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv214 · Cited by 43
“Twelve genes were downregulated in the animals exposed to nonfibrogenic compounds and upregulated in fibrogenic compound dose groups (>6 1.5-fold [average] represented by dashed lines in Figure 9 and listed in Table 3; Col1a1, Col1a2, Col4a1, Cp, Cyba, Fbn1, Itgal, Itgb2, procollagen C-endopeptidase enhancer [Pcolce],…”
BackgroundInfluentialJeong, J., García‐Reyero, N., Burgoon, L. D., Perkins, E. J., Park, T.-H., Kim, C., Roh, J., & Choi, J. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00040 · Cited by 44
Immunologic and imaging signatures in post tuberculosis lung disease
Singh, S., Allwood, B., Chiyaka, T., Kleyhans, L., Naidoo, C., Moodley, S., Theron, G., & Segal, L. N. (2022) · Tuberculosis · doi:10.1016/j.tube.2022.102244 · Cited by 64
The Role of Airway Myofibroblasts in Asthma
Jendzjowsky, N. G., & Kelly, M. M. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.1917 · Cited by 46
Chen, Y., Yang, S., Yao, W., Zhu, H., Xu, X., Meng, G., & Zhang, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098483 · Cited by 44
“In order to determine whether PPAR is involved in the attenuating effects of beraprost on Ang IIinduced CFs proliferation and collagen I synthesis, CFs were preincubated with GW9662 (a specific antagonist of PPAR c, 10 mM) [37] for 4 h following with beraprost treatment and Ang II stimulation.”
MethodRegulation of Myofibroblast Differentiation by Poly(ADP-Ribose) Polymerase 1
Hu, B., Wu, Z. B., Hergert, P. J., Henke, C. A., Bitterman, P. B., & Phan, S. H. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.09.004 · Cited by 41
“Additionally, various studies have demonstrated PARylation of Smad3,(28,29) PPARg,(30,31) and DNA methyltransferase 1 (Dnmt1),(32) known regulators of myofibroblast differentiation.(8,11,31) However, the precise role of PARP-1 in the regulation of myofibroblast differentiation has not been determined.”
BackgroundRoles of lipid metabolism and its regulatory mechanism in idiopathic pulmonary fibrosis: A review
Tian, Y., Duan, C., Feng, J., Liao, J., Yang, Y., & Sun, W. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106361 · Cited by 43
Cui, Y., Jiang, L., Yu, R., Shao, Y., Mei, L., & Tao, Y. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112096 · Cited by 42
Intestinal Myofibroblast TRPC6 Channel May Contribute to Stenotic Fibrosis in Crohnʼs Disease
Kurahara, L. H., Sumiyoshi, M., Aoyagi, K., Hiraishi, K., Nakajima, K., Nakagawa, M., Hu, Y., & Inoue, R. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000295 · Cited by 40
“These results support a previously proposed model that activation of the PI3K–AKT pathway by TGF-b is crucial in myofibroblastic differentiation.(29) Because TRPC6 siRNA did not affect Akt phosphorylation, we speculate that TRPC6 is at the downstream of Akt (see Fig.”
ResultBaranowski, A., Schlemmer, L., Förster, K., Slotina, E., Mickan, T., Truffel, S., Klein, A., Mattyasovszky, S. G., Hofmann, A., Ritz, U., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s204135 · Cited by 41
Gomart, A., Vallée, A., & Lecarpentier, Y. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.713344 · Cited by 42
Peng, H., Wang, R.-X., Deng, H., Wang, Y., Tang, J.-D., Cao, F.-Y., & Wang, J. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6402 · Cited by 37
Lecarpentier, Y., Gourrier, E., Gobert, V., & Vallée, A. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00176 · Cited by 45
Yao, H., & Li, J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.219816 · Cited by 41
“…methylation, microRNA (miRNA), and histone post-translational modifications, play important roles in regulating the injury and repair during organ fibrosis (Kim and Shukla, 2005; Kulkarni et al., 2011; Zhang et al., 2011; He et al., 2012; Komatsu et al., 2012; Zhou et al., 2012; Li et al., 2014).”
BackgroundAnti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts
Koo, J. B., Nam, M.-O., Jung, Y., Yoo, J., Kim, D. H., Kim, G., Shin, S. J., Lee, K. M., Hahm, K. B., Kim, J. W., et al. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0627-4 · Cited by 40
“PI3 kinase/Akt pathway activation by TGF-β1 has been shown to be crucial in TGF-β1 induced fibrogenesis in several tissues including intestine [21, 23, 36, 41, 42].”
BackgroundInfluentialChoi, Y. J., Koo, J. B., Kim, H. Y., Seo, J. W., Lee, E. J., Kim, W. R., Cho, J. Y., Hahm, K. B., Hong, S. P., Kim, D. H., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1385-8 · Cited by 35
Zhou, B., Buckley, S. T., Patel, V., Liu, Y., Luo, J., Krishnaveni, M. S., Ivan, M., DeMaio, L., Kim, K., Ehrhardt, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038827 · Cited by 33
“These data suggest that inhibitory effects of PPARc ligands on EMT are dependent on their physical properties, similar to a previous report in the context of fibroblast-myofibroblast differentiation [23].”
BackgroundResultFerreira, B. P., Costa, G., Mascarenhas‐Melo, F., Pires, P. C., Heidarizadeh, F., Giram, P. S., Mazzola, P. G., Cabral, C., Veiga, F., & Paiva‐Santos, A. C. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09860-5 · Cited by 38
“…with antifibrotic activity, both by activating signaling pathways that lead to decreased pro-inflammatory cytokines (Odegaard et al. 2007) and by limiting fibroblast activation by transforming growth factor b (TGF-b1) (Kulkarni et al. 2011), which has profibrotic properties (Kitani et al. 2003).”
BackgroundRamon, S., Bancos, S., Thatcher, T. H., Murant, T. I., Moshkani, S., Sahler, J., Bottaro, A., Sime, P. J., & Phipps, R. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200956 · Cited by 33
Self-citationLiu, D., Gong, L., Zhu, H., Pu, S., Wu, Y. B., Zhang, W., & Huang, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00419 · Cited by 38
“In fetal lung fibroblasts, TGF-β activates Akt signaling via p38 Mitogen Activated Protein Kinase (MAPK) and Focal Adhesion Kinase (FAK; Kulkarni et al., 2011).”
BackgroundInfluentialZhang, X., Lan, D., Ning, S., Jia, H., & Yu, S. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4226 · Cited by 41
IL-13 Induces YY1 through the AKT Pathway in Lung Fibroblasts
Guo, J., Yao, H., Lin, X., Xu, H., Dean, D. A., Zhu, Z., Liu, G., & Sime, P. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119039 · Cited by 31
“AKT phosphorylation occurs in the lungs of IPF patients and in fibrotic animal models [28,29,30].”
Self-citationKiss, K., Baghy, K., Spisák, S., Szanyi, S., Tulassay, Z., Zalatnai, A., Löhr, M. J., Jesenofsky, R., Kovalszky, I., & Firneisz, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128059 · Cited by 31
“PPARγ agonists had inhibitory effect on hepatic stellate cell growth in a hepatic fibrosis model [40] and PPARγ ligand also inhibited the TGF-β-mediated lung myofibroblast differentiation [41] suggesting that downregulation of PPARγmay be a profibrogenic signal.”
BackgroundJärvinen, P. M., & Laiho, M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.12.004 · Cited by 31
PTEN inhibits proliferation and functions of hypertrophic scar fibroblasts
Guo, L., Chen, L., Bi, S., Chai, L., Wang, Z., Cao, C., Tao, L., & Li, S. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1100-2 · Cited by 28
Hassan, N. H., Kamel, G. M., Fayed, H. M., Korany, R. M. S., & Ramadan, A. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2496661 · Cited by 34
“Through “the PI3K/Akt (phosphotidylinositol-3-kinase/Protein Kinase B/PKB) pathway”, TGF-β 1 causes myofibroblasts to differentiate, which leads to liver fibrosis [63].”
Metadata
- Authors
- Kulkarni, A. A., Thatcher, T. H., Olsen, K. C., Maggirwar, S. B., Phipps, R. P., & Sime, P. J.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Sime, Patricia J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-06
- Volume
- 6
- Issue
- 1
- Pages
- e15909
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3017065
- OpenAlex
- W1991127474
- Cited by
- 189
- References
- 60
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 13 · 2022: 11 · 2021: 12 · 2020: 7 · 2019: 22 · 2018: 10 · 2017: 16 · 2016: 10 · 2015: 16 · 2014: 10 · 2013: 9 · 2012: 22
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Rochester
- National Institutes of Health (ES01247, ES-07026)
- National Heart, Lung, and Blood Institute (R03HL095402, F30HL097596, T32HL066988, HL075432-04S2, HL095402-02, HL075432-04S1, R01HL075432, HL075432)
- National Institute of Environmental Health Sciences (P30ES001247, T32ES007026)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- PPARγ ligands, TGF-beta signaling, myofibroblast differentiation, pulmonary fibrosis, idiopathic pulmonary fibrosis, PI3K/Akt signaling, Akt phosphorylation, CDDO, prostaglandin A1, FAK phosphorylation, lung fibroblasts
- MeSH terms
- Cell Differentiation, Fibrosis, Humans, Ligands, Phosphorylation, Signal Transduction, Transforming Growth Factor beta, PPAR gamma, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.